Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on TriSalus Life Sciences. The associated price target remains the same with $16.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors including TriSalus Life Sciences’ strong financial performance and strategic advancements. The company reported impressive sales growth for its TriNav system, with revenue exceeding expectations and showing significant year-over-year and quarter-over-quarter increases. This growth is supported by the company’s commitment to expanding its commercial efforts, particularly in liver-directed therapies.
Additionally, TriSalus has made strategic moves to improve its financial structure, such as completing a preferred stock conversion, which enhances its capital structure. The company is also on track to achieve positive cash flow and EBITDA by the first half of 2026, supported by declining R&D expenses as certain programs wind down. The launch of the TriNav FLX infusion system and the expansion of reimbursement coverage further bolster the company’s market position, making it a compelling investment opportunity.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $11.00 price target.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TLSI in relation to earlier this year.